Sign in

CIK 0001479419

  • Non-accelerated filer
  • Smaller reporting company

KALA BIO, Inc.

Sign in to watch
Ticker
KALA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
270604595
Phone
+1 781-996-5252
Business address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 02476
Former names
KALA BIO, Inc., Kala Pharmaceuticals, Inc.
  1. 4 Open-market sale CHIEF FINANCIAL OFFICER sold 1,706 shares at $7.63 ($13,017)
  2. 4 Open-market buy 10% owner bought 310,559 shares at $6.44 ($2,000,000)
  3. 3 Insider Initial Statement of Ownership
  4. 4 Open-market sale SEE REMARKS sold 4,653 shares at $4.75 ($22,102)
  5. 4 Open-market sale CHIEF BUSINESS OFFICER sold 5,158 shares at $4.75 ($24,501)
  6. 4 Open-market sale CHIEF FINANCIAL OFFICER sold 4,163 shares at $4.75 ($19,774)
  7. 4 Open-market sale CHIEF EXECUTIVE OFFICER sold 15,168 shares at $4.75 ($72,048)
  8. 4 Open-market sale SEE REMARKS sold 5,489 shares at $4.75 ($26,073)
  9. 4 Grant or award Director acquired 1,400 shares (grant or award)
  10. 4 Grant or award Director acquired 1,400 shares (grant or award)
  11. 4 Grant or award Director acquired 1,400 shares (grant or award)
  12. 4 Grant or award Director acquired 1,400 shares (grant or award)
  13. 4 Grant or award Director acquired 1,750 shares (grant or award)
  14. 4 Grant or award Director acquired 1,400 shares (grant or award)
  15. 4 Open-market sale SEE REMARKS sold 2,093 shares at $6.09 ($12,746)
  16. 4 Open-market sale CHIEF BUSINESS OFFICER sold 231 shares at $6.09 ($1,407)
  17. 4 Open-market sale CHIEF FINANCIAL OFFICER sold 1,786 shares at $6.09 ($10,877)
  18. 4 Open-market sale SEE REMARKS sold 2,002 shares at $6.09 ($12,192)
  19. 4 Open-market sale CHIEF EXECUTIVE OFFICER sold 7,392 shares at $6.09 ($45,017)
  20. 4 Open-market sale SEE REMARKS sold 1,227 shares at $6.74 ($8,270)

Page 3 of 15 · 288 filings